Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

GSM6454745

— · A

5205170f-a88f-54f9-8f7d-30bff9aecb0b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
  • APICAL_SURFACE+0.380
  • COAGULATION+0.380
  • UV_RESPONSE_DN+0.380
  • KRAS_SIGNALING_UP+0.370
  • TGF_BETA_SIGNALING+0.350
  • ESTROGEN_RESPONSE_EARLY+0.310
  • ALLOGRAFT_REJECTION+0.290
  • COMPLEMENT+0.290
  • ANGIOGENESIS+0.270

Top 10 suppressed

  • E2F_TARGETS-0.530
  • G2M_CHECKPOINT-0.480
  • MTORC1_SIGNALING-0.460
  • MYC_TARGETS_V1-0.450
  • MYC_TARGETS_V2-0.430
  • CHOLESTEROL_HOMEOSTASIS-0.340
  • OXIDATIVE_PHOSPHORYLATION-0.330
  • DNA_REPAIR-0.220
  • MITOTIC_SPINDLE-0.220
  • GLYCOLYSIS-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-50-8459-01A-11R-2326-07
lung-landscapes@6
—cohortMD20.923
22cec663c-00c8-48b5-967b-f2a53c0fb409
colon-landscapes@1
——0.919
3TCGA-55-7227-01A-11R-2039-07
lung-landscapes@6
—cohortA10.915
4SRR8518128
breast-umap@18
—A0.912
5SRR12475153
colon-landscapes@1
——0.911
6TCGA-38-7271-01A-11R-2039-07
lung-landscapes@6
—cohortMD20.910
7SRR5088925
melanoma-umap@29
——0.909
8TCGA-75-7030-01A-11R-1949-07
lung-landscapes@6
—cohortA10.903
9TCGA-E2-A1IJ-01A-11R-A144-07
breast-umap@18
—A0.902
1020020074.LumA
breast-umap@18
—A0.901

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.430Inavolisib— uncovered
APICAL_SURFACE0.380Temsirolimus— uncovered
COAGULATION0.380Binimetinib— uncovered
UV_RESPONSE_DN0.380Inavolisib— uncovered
KRAS_SIGNALING_UP0.370Inavolisib— uncovered
TGF_BETA_SIGNALING0.350Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.310Inavolisib— uncovered
ALLOGRAFT_REJECTION0.290Idelalisib— uncovered
COMPLEMENT0.290Inavolisib— uncovered
ANGIOGENESIS0.270Remibrutinib— uncovered
APICAL_JUNCTION0.270Inavolisib— uncovered
IL2_STAT5_SIGNALING0.250Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.240Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.240Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.220Idelalisib— uncovered
MYOGENESIS0.190Inavolisib— uncovered
KRAS_SIGNALING_DN0.160Remibrutinib— uncovered
APOPTOSIS0.130Idelalisib— uncovered
HEDGEHOG_SIGNALING0.130Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.120Idelalisib— uncovered